Oncology
Refine Search
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Swiss cancer giant Novartis has entered into an exclusive worldwide licensing and collaboration deal with Ratio Therapeutics, aiming to develop a next-generation radiotherapeutic. 19 November 2024
Pharmaceutical
German pharma, science and technology company Merck KGaA today confirmed its forecast for fiscal 2023 despite a difficult market environment in the third quarter. 9 November 2023
Biotechnology
Britain’s biggest drugmaker AstraZeneca has exceeded revenues expectations handily in the third quarter 2023, with robust demand in oncology leading the way. 9 November 2023
Pharmaceutical
Japanese drug major Takeda has received US approval for Fruzaqla (fruquintinib), an oral targeted therapy for bowel cancer. 9 November 2023
Generics
German pharmaceutical major Bayer has refused compensation of more than 400 million roubles ($4.3 million) from Russian Nativa (renamed Spectrum) for the use of patents on the anticancer drug Nexavar (sorafenib), reports The Pharma Letter’s local correspondent. 9 November 2023
Biotechnology
Californian drugmaker Gilead Sciences has exceeded estimates in the third quarter, with revenues of around $7.1 billion and earnings per share (EPS) of $1.73. 8 November 2023
Pharmaceutical
German life sciences major Bayer has confirmed its group outlook for 2023 after posting third-quarter figures that were down against the previous year. 8 November 2023
Pharmaceutical
Privately-held Italian drugmaker Menarini and USA/China-based SciClone Pharmaceuticals have entered into an exclusive sub-licensing agreement to develop and commercialize Orserdu (elacestrant) in China. 8 November 2023
Pharmaceutical
Italian pharma major Recordati saw its shares rise 3.6% to 45.57 euros yesterday, after it released a strong set of financial results for the first-nine months of 2023. 8 November 2023
Biotechnology
Danish drugmaker Genmab has reported third quarter 2023 revenues of 4.7 billion Danish kroner ($420 million), better than the 4.5 billion kroner expected according to the FT consensus forecast. 8 November 2023
Biotechnology
A biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer, is to go by a new name. 7 November 2023
Biotechnology
A collaboration between Senti Biosciences and Celest Therapeutics will see the latter gain rights to develop SENTI-301A in China. 7 November 2023
Biotechnology
San Mateo, USA-based biotech start-up Cargo Therapeutics, which is specializing in cancer treatments, set terms for its initial public offering (IPO) early Monday with plans to offer 18.8 million shares priced at $15 to $17 each. 7 November 2023
Pharmaceutical
Anastrozole, which has been used for many years as a breast cancer treatment, has today been licensed by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as a preventive option – which it is hoped could help prevent around 2,000 cases of breast cancer in England. 7 November 2023
Biotechnology
Kronos Bio is to cut around 19% of its staff as part of a plan to extend its cash runway into 2026. 6 November 2023
Biotechnology
Shares of German biotech BioNTech were up 5.3% at $100.91, despite joining the list of companies with downturned sales and earnings as the COVID-19 pandemic subsides. 6 November 2023
Biotechnology
In another antibody-drug conjugate (ADC) deal for the US pharma major, Bristol Myers Squibb has acquired USA and South Korea-based Orum Therapeutics’ ORM-6151 program. 6 November 2023
Biotechnology
UK-based biotech Roquefort Therapeutics has announced that its mesodermal killer (MK) cell program has reached a significant milestone. 6 November 2023
Biotechnology
San Diego, USA-based precision medicine firm Kura Oncology’s shares rose 4% to $8.31 yesterday, after it announced a research collaboration with Mirati Therapeutics. 3 November 2023
Biotechnology
Eli Lilly has reported strong revenues for the third quarter, with blockbuster diabetes med Mounjaro (tirzepatide) doing much of the heavy lifting. 2 November 2023
Biotechnology
The European Medicines Agency (EMA) has validated the submission for Braftovi (encorafenib) with Mektovi (binimetinib), submitted by privately-held French drugmaker Pierre Fabre, for the treatment of adult patients with BRAFV600-mutant advanced non-small cell lung cancer (NSCLC). 2 November 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze